News

EMPHNET Conducts Sero-Epidemiologic Investigation of MERS-CoV in Survivors, Contacts for Jordan’s 2015 Cases
    EMPHNET Conducts Sero-Epidemiologic Investigation of MERS-CoV in Survivors, Contacts for Jordan’s 2015 Cases
    April 26, 2016   |  Jordan

    EMPHNET, in collaboration with the Centers for Disease Control and Prevention (CDC) and the Jordanian Ministry of Health, conducted a sero-epidemiologic investigation for survivors and contacts of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The investigation was done for the cases identified in 2015, and it was performed in hospitals in Amman and Zarqa between April 2 and 7, 2016.

    EMPHNET Conducts Sero-Epidemiologic Investigation of MERS-CoV in Survivors, Contacts for Jordan’s 2015 Cases

    The first known cases of MERS-CoV in Jordan occurred in Zarqa between March and April of 2012.  New cases and clusters of the MERS-CoV infections continue to occur within the Arabian Peninsula and have been exported to other countries around the world. Little is known regarding the duration of antibody responses following MERS-CoV exposure and infection. Moreover, for the first time, a large-scale deletion in the MERS coronavirus has been identified. Notably, all MERS cases in Jordan of 2015 were identified as having this deletion.

    EMPHNET Conducts Sero-Epidemiologic Investigation of MERS-CoV in Survivors, Contacts for Jordan’s 2015 Cases

    It is for this reason that the sero-epidemiologic investigation has been conducted. It is urgently needed to identify whether or not these deletions affected the transmissibility or pathogenicity of this particular MERS-CoV strain.

    EMPHNET Conducts Sero-Epidemiologic Investigation of MERS-CoV in Survivors, Contacts for Jordan’s 2015 Cases

    The investigation comes as part of EMPHNET’s work in the area of communicable diseases. Such efforts aim to reduce the morbidity and mortality of preventable diseases among at-risk populations in the Eastern Mediterranean Region (EMR).

    As a serious respiratory illness, MERS-CoV can progress rapidly to respiratory failure and death in approximately 40% of laboratory confirmed cases.